Geron Corp GERN
We take great care to ensure that the data presented and summarized in this overview for GERON CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GERN
View all-
Black Rock Inc. New York, NY41.4MShares$144 Million0.0% of portfolio
-
State Street Corp Boston, MA31.6MShares$110 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT30.5MShares$106 Million3.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.9MShares$104 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA27.2MShares$94.5 Million12.02% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA17.4MShares$60.3 Million6.04% of portfolio
-
Orbimed Advisors LLC San Diego, CA12.9MShares$44.7 Million0.96% of portfolio
-
Nea Management Company, LLC Timonium, MD12.8MShares$44.3 Million2.96% of portfolio
-
Geode Capital Management, LLC Boston, MA11.4MShares$39.6 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA10.9MShares$38 Million0.01% of portfolio
Latest Institutional Activity in GERN
Top Purchases
Top Sells
About GERN
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Insider Transactions at GERN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2024
|
V Bryan Lawlis |
SELL
Open market or private sale
|
Direct |
35,000
-100.0%
|
$105,000
$3.75 P/Share
|
|
May 15
2024
|
V Bryan Lawlis |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+50.0%
|
$35,000
$1.94 P/Share
|
|
Dec 29
2023
|
Robert J. Spiegel |
BUY
Grant, award, or other acquisition
|
Direct |
3,406
+2.03%
|
-
|
|
Dec 29
2023
|
Gaurav Aggarwal |
BUY
Grant, award, or other acquisition
|
Direct |
1,970
+50.0%
|
-
|
|
Dec 29
2023
|
Susan Molineaux |
BUY
Grant, award, or other acquisition
|
Indirect |
6,220
+4.55%
|
-
|
|
Sep 29
2023
|
Robert J. Spiegel |
BUY
Grant, award, or other acquisition
|
Direct |
3,390
+2.07%
|
-
|
|
Sep 29
2023
|
Susan Molineaux |
BUY
Grant, award, or other acquisition
|
Indirect |
6,191
+4.74%
|
-
|
|
Aug 24
2023
|
Elizabeth G. O'Farrell |
BUY
Open market or private purchase
|
Indirect |
6,579
+20.06%
|
$13,158
$2.28 P/Share
|
|
Aug 24
2023
|
Elizabeth G. O'Farrell |
BUY
Open market or private purchase
|
Direct |
6,607
+47.15%
|
$13,214
$2.28 P/Share
|
|
Jun 30
2023
|
Susan Molineaux |
BUY
Grant, award, or other acquisition
|
Indirect |
4,088
+3.35%
|
-
|
|
Jun 30
2023
|
Anil Kapur EVP, CORP STRATEGY & CCO |
BUY
Grant, award, or other acquisition
|
Direct |
7,567
+11.07%
|
$15,134
$2.04 P/Share
|
|
Jun 30
2023
|
Robert J. Spiegel |
BUY
Grant, award, or other acquisition
|
Direct |
2,239
+1.4%
|
-
|
|
May 11
2023
|
V Bryan Lawlis |
SELL
Open market or private sale
|
Direct |
35,000
-100.0%
|
$105,000
$3.0 P/Share
|
|
May 11
2023
|
V Bryan Lawlis |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+50.0%
|
$35,000
$1.1 P/Share
|
|
May 01
2023
|
Susan Molineaux |
SELL
Open market or private sale
|
Direct |
35,000
-100.0%
|
$70,000
$2.48 P/Share
|
|
May 01
2023
|
Susan Molineaux |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+50.0%
|
$35,000
$1.1 P/Share
|
|
Mar 31
2023
|
Robert J. Spiegel |
BUY
Grant, award, or other acquisition
|
Direct |
3,312
+2.09%
|
-
|
|
Mar 31
2023
|
Susan Molineaux |
BUY
Grant, award, or other acquisition
|
Indirect |
6,048
+5.04%
|
-
|
|
Feb 10
2023
|
John A Scarlett CHAIRMAN, PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
446,668
-100.0%
|
$1,340,004
$3.0 P/Share
|
|
Feb 10
2023
|
John A Scarlett CHAIRMAN, PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
446,668
+50.0%
|
$446,668
$1.5 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 35K shares |
|---|---|
| Grant, award, or other acquisition | 35.1K shares |
| Open market or private purchase | 13.2K shares |
| Open market or private sale | 35K shares |
|---|